What locus composition & criteria to consider for MSI kit design? Optimize sensitivity and clinical accuracy.

The composition of microsatellite loci and the classification thresholds you select will determine your assay’s clinical sensitivity and specificity for Lynch syndrome screening.
The National Cancer Institute (NCI) established a foundational panel of five markers—two mononucleotide repeats (BAT25, BAT26) and three dinucleotide repeats (D5S346, D2S123, D17S250)—defining high‑level instability (MSI‑H) as two or more unstable loci. However, modern kits increasingly favor all‑mononucleotide repeat panels and adopt a proportional cutoff (>30% of markers unstable) when more than five loci are tested. Your choice must balance detection sensitivity, interpretability, and the technical constraints of multiplex PCR.

To build a robust MSI detection kit for Lynch syndrome screening, prioritize a panel of at least five quasi‑monomorphic mononucleotide repeat loci and adopt a clear classification rule—either ≥2 unstable markers for a 5‑plex or >30% for larger panels. This maximizes capture of mismatch‑repair deficient tumors while minimizing ambiguous MSI‑Low calls.

The Foundation: Selecting the Optimal Locus Composition

Why Mononucleotide Repeats Outperform Dinucleotide Markers

Mononucleotide repeats (e.g., BAT25, BAT26, NR‑21, NR‑24) are quasi‑monomorphic in the general population, meaning their allele lengths vary minimally among individuals.
This stability in normal tissue makes any length shift in tumor DNA highly suspicious for mismatch repair (MMR) deficiency, delivering superior sensitivity and cleaner signal than dinucleotide repeats.
Dinucleotide markers (D5S346, D2S123, D17S250) are more polymorphic, increasing the risk of false‑positive instability calls and reducing overall specificity.

The Classic NCI Panel – A Starting Point, Not the Endpoint

The original Bethesda/NCI panel recommended two mononucleotide (BAT25, BAT26) and three dinucleotide repeats, with MSI‑H defined as instability in ≥2 of the 5 markers.
While historically important, numerous studies have shown that this mix of repeat types misses a fraction of MMR‑deficient tumors, especially those with less pronounced dinucleotide instability.
Diagnostic developers should treat this panel as a regulatory benchmark but move toward higher‑sensitivity designs for modern screening.

Modern All‑Mononucleotide Panels for Maximum Sensitivity

Replacing dinucleotide loci with additional mononucleotide markers dramatically improves performance.
The Promega pentaplex (BAT‑25, BAT‑26, NR‑21, NR‑24, MONO‑27) is a widely validated example that uses five quasi‑monomorphic mononucleotide repeats.
Other research‑backed loci, such as SCL7A8, KIT, ZNF2, MAP4K3, and repeats within MSH2, can be added to expand the marker set and increase the confidence of instability calls—especially useful for large, NGS‑based panels.

Designing for Multiplex PCR: Polymerase Choice and Amplicon Design

A successful kit must amplify all selected microsatellites in a single reaction with minimal artifacts.
This requires a high‑fidelity, hot‑start DNA polymerase to reduce PCR stutter peaks that mimic small insertions or deletions.
Fluorescently labeled primers must be optimized so that amplicon sizes do not overlap across markers, and the stutter pattern of each repeat is well characterized to avoid false instability calls.

Setting Clear Classification Criteria: When Is a Tumor “Unstable”?

The Dichotomous Rule for Small Panels (5 Markers)

For a 5‑marker panel, the clinically validated rule is straightforward:

• MSI‑High (MSI‑H): instability in ≥2 loci.
• MSI‑Low (MSI‑L): instability in exactly 1 locus.
• Microsatellite Stable (MSS): instability in 0 loci.
  This system aligns with the NCI framework and is easily implemented when loci are carefully chosen to be independently informative.

The Proportional Approach for Expanded Panels (>5 Markers)

When your panel contains 10, 15, or more microsatellite markers, a simple count becomes unreliable.
The consensus is to classify a specimen as MSI‑High if >30% of the tested markers show instability.
This threshold remains consistent across multiple platforms (capillary electrophoresis, qPCR, NGS) and mirrors the biological expectation that MMR‑deficient tumors accumulate widespread microsatellite shifts.

Avoiding the MSI‑L Trap in Clinical Interpretation

In many populations, MSI‑Low tumors behave clinically and molecularly like MSS tumors and are not associated with germline MMR mutations.
Many diagnostic guidelines now advocate a binary reporting scheme (MSI‑H vs. non‑MSI‑H), effectively merging MSI‑L with MSS to simplify Lynch syndrome screening.
If your kit reports MSI‑L, include clear interpretive comments to prevent unnecessary genetic counseling downstream.

Correlating MSI Status with MMR Immunohistochemistry

MSI PCR and MMR protein IHC are complementary; a well‑designed kit should anticipate concurrent use.
Loss of MLH1/PMS2 or MSH2/MSH6 expression on IHC usually corroborates MSI‑H status.
Developers can provide concordance guidance—for example, if MSI‑H is present but IHC shows intact MMR proteins, recommend further work‑up to rule out a non‑functional but antigenic protein.

Understanding the Trade‑offs and Common Pitfalls

Stutter Artifacts and the Cost of Low Fidelity

All microsatellite amplification produces some stutter bands due to polymerase slippage.
An enzyme with low strand‑displacement and high processivity (often a hot‑start blend with a proofreading component) minimizes these artifacts, preserving the true allele peak.
Poor enzyme selection can generate false shifts that mimic instability, particularly in mononucleotide runs.

Tumor Cellularity and DNA Input Quality

Specimens with less than 20% tumor nuclei risk diluting the mutant signal, yielding a false‑negative MSS result.
Many assay protocols recommend macrodissection or enrichment steps to ensure tumor DNA represents the majority of the template.
The kit’s instructions should define the minimum tumor content and the required DNA quantity to avoid erroneous classifications.

The Pitfall of Dinucleotide Repeat Polymorphism

Dinucleotide markers like D5S346 and D2S123 exhibit germline polymorphism; the “normal” allele lengths vary widely in the population.
This can lead to an apparent shift in tumor DNA when compared to a mismatched normal reference, generating a false‑positive instability call.
Moving to mononucleotide‑only panels—where normal alleles are nearly fixed—eliminates this source of error.

Balancing Sensitivity and Specificity in a Lynch Screening Population

The primary goal of an MSI screen is to detect every tumor that might harbor a germline MMR mutation (high sensitivity), while keeping the false‑positive rate low enough that genetic services are not overwhelmed.
Over‑calling MSI‑H forces unnecessary germline testing, anxiety, and resource use.
The combination of a well‑curated mononucleotide panel, a validated detection algorithm, and an appropriate instability threshold achieves this balance.

Making the Right Choice for Your Diagnostic Goal

The optimal locus set and classification criteria depend on your intended clinical workflow and the population you serve. Consider the following guiding statements.

• If your primary focus is high sensitivity for Lynch syndrome: Use a panel of ≥5 quasi‑monomorphic mononucleotide repeats with a >30% instability threshold, and pair the assay with MMR IHC to confirm loss of protein expression.
• If your goal is alignment with historic NCI guidelines and regulatory familiarity: Include the classic BAT25, BAT26, D5S346, D2S123, and D17S250, classify with the ≥2/5 rule, but acknowledge the higher false‑negative risk from dinucleotide markers in your labeling.
• If simplicity and a binary output are paramount: Design a 5‑plex mononucleotide‑only kit and report only MSI‑H vs. non‑MSI‑H (treating one‑locus instability as MSS); this mirrors most clinical action algorithms.
• If you are targeting both hereditary and sporadic MSI‑H populations: Consider adding coding microsatellites such as TGFBR2 or BAX to your expanded panel—these provide prognostic and pathway‑specific information without compromising the original screening question.

By anchoring your kit on a core of high‑performance mononucleotide markers and a clear, evidence‑based classification rule, you give laboratories the power to reliably identify Lynch‑spectrum cancers and direct patients toward life‑saving surveillance and intervention.

Summary Table:

Accelerate your molecular assay development with CamelBio. We provide diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials—such as high-fidelity hot-start polymerases and custom assay reagents—alongside expert technical services and consulting from concept to clinic. Contact CamelBio today to optimize your MSI detection platform!